CLOV CLOVER HEALTH INV CORP

Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patients

WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant (“CA”) use is associated with better management of congestive heart failure (“CHF”). The analysis, titled “,” details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PCP that uses Counterpart Assistant.

Key highlights of the study include:

  • A relationship with a CA provider was associated with better outcomes, including a lower average number of all-cause hospitalizations (18% lower) and 30-day readmissions (25% lower) for CHF patients enrolled in Clover Health’s Medicare Advantage (MA) plans.
  • CA provides actionable insights at the point of care, which supports earlier detection of chronic disease, tracking of disease progression and severity, and guideline-based treatment.
  • A relationship with a PCP who uses CA was associated with better clinical care for patients with CHF, including higher rates of outpatient cardiologist visits and in-home care management.

"At Counterpart Health, we are committed to developing technology solutions that truly augment the capabilities of our healthcare providers," stated Dr. David Tsay MD, PhD, Chief Medical Officer of Counterpart Health and co-author of the whitepaper. "The results of this study on Counterpart Assistant and congestive heart failure demonstrate how providing clinicians with timely, data-driven insights can help lead to significant improvements in patient outcomes. This technology is designed to be a collaborative partner, empowering them to deliver even more effective and personalized care."

CA has empowered providers in patient care by focusing on clinical excellence in chronic disease detection and management, emphasizing proactive interventions and longitudinal care. Congestive heart failure in particular is a prevalent and potentially debilitating chronic condition that poses a substantial burden on patients in the Medicare population. According to CMS, heart failure is the leading cause of hospitalizations among older adults, and Medicare enrollees with heart failure have the highest readmission rate of any condition.

“For value-based care to truly succeed, we must prioritize proactive and effective management of chronic diseases,” said Conrad Wai, CEO of Counterpart Health. “Counterpart Assistant is a testament to this commitment, offering clinicians actionable intelligence that can translate to improved care for patients with heart failure and a significant decrease in costly acute episodes. This technology demonstrates that enhanced clinical quality and reduced cost of care delivery are not mutually exclusive, but rather, achievable through intelligent physician enablement.”

This is the fourth retrospective data analysis conducted by the Company to measure the clinical impact of CA on the identification and management of chronic diseases. The previous analyses focus on the earlier diagnosis and treatment of and , and the technology’s impact on .

To learn more about Counterpart Health, visit: .

About Counterpart Health

, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI powered physician enablement platform. Counterpart Health’s flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health’s Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology’s impact on , as well as the earlier identification and management of and .

Investor Relations:

Ryan Schmidt

Press Inquiries:



EN
01/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CLOVER HEALTH INV CORP

 PRESS RELEASE

Clover Health to Participate in Upcoming Leerink 2026 Global Healthcar...

Clover Health to Participate in Upcoming Leerink 2026 Global Healthcare Conference WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Leerink 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 9:20 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at . About Clover Health:Clover Health (Nasdaq: CLOV) i...

 PRESS RELEASE

Clover Health to Report Fourth Quarter and Full Year 2025 Financial Re...

Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter. Fourth Quarter and Full Year 2025 Conference Webcast Detail...

 PRESS RELEASE

Clover Health Announces 53% Growth in Medicare Advantage Membership Du...

Clover Health Announces 53% Growth in Medicare Advantage Membership During AEP, Increasing to 153,000 Members as of January 1, 2026; Expects First-Ever Full Year GAAP Net Income Profitability in 2026 Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026.Disciplined, core-market growth, strong returning member retention, and improving cohort economics position Clover for compounding earnings and margin expansion.Powered by AI, Clover continues to bring industry-leading clinical quality to...

 PRESS RELEASE

Counterpart Health 2025 Results: How Better Clinical Decisions at Scal...

Counterpart Health 2025 Results: How Better Clinical Decisions at Scale Improve Outcomes, Quality, and Cost Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and financial outcomes SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- , Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research ...

 PRESS RELEASE

Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare C...

Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare Conference WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026, at 11:15 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at . About Clover Health:Clover Health (Nasdaq: CLOV) is a p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch